Corcept Therapeutics Incorporated (CORT)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 675,040 | 628,555 | 569,610 | 523,529 | 482,375 | 450,026 | 428,153 | 413,824 | 401,858 | 397,624 | 392,027 | 380,229 | 365,978 | 352,891 | 343,087 | 340,064 | 353,874 | 356,034 | 351,212 | 334,904 |
Total current assets | US$ in thousands | 471,602 | 466,978 | 560,846 | 503,367 | 458,636 | 431,527 | 432,588 | 528,179 | 498,707 | 452,402 | 427,555 | 388,220 | 381,387 | 401,900 | 411,270 | 409,624 | 524,247 | 463,493 | 438,333 | 391,836 |
Total current liabilities | US$ in thousands | 140,773 | 126,216 | 100,750 | 97,202 | 104,505 | 121,873 | 93,059 | 25,216 | 81,588 | 53,068 | 54,038 | 57,244 | 6,908 | 44,757 | 45,402 | 40,601 | 10,554 | 43,048 | 42,243 | 36,005 |
Working capital turnover | 2.04 | 1.84 | 1.24 | 1.29 | 1.36 | 1.45 | 1.26 | 0.82 | 0.96 | 1.00 | 1.05 | 1.15 | 0.98 | 0.99 | 0.94 | 0.92 | 0.69 | 0.85 | 0.89 | 0.94 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $675,040K ÷ ($471,602K – $140,773K)
= 2.04
Corcept Therapeutics Incorporated's working capital turnover has demonstrated fluctuations over the analyzed periods, based on the provided data. The ratio has varied between 0.69 and 2.04, indicating changes in the efficiency with which the company has been able to utilize its working capital to generate revenue.
In the initial periods, from December 2020 to March 2022, the working capital turnover remained relatively stable around the range of 0.69 to 1.15. From June 2022 onwards, there was an upward trend observed, with the ratio reaching a peak of 2.04 by December 31, 2024.
A working capital turnover ratio greater than 1 suggests that the company is effectively using its working capital to generate sales. The significant increase in the ratio from September 2024 to December 2024 may indicate improved efficiency in managing working capital or an increase in sales relative to the working capital invested.
Overall, the analysis of Corcept Therapeutics Incorporated's working capital turnover indicates varying levels of efficiency in utilizing working capital over time, with a notable improvement in recent periods. This suggests potential enhancements in the company's operational performance and financial management.
Peer comparison
Dec 31, 2024